Business

Cubist executives see 2014 as a pivotal year in their fight against antibiotic-resistant ‘superbugs’

Above, a worker at Cubist’s Lexington facility. Regulators have accepted for review Cubist’s drug for treatment of infections such as methicillin-resistant Staphylococcus aureus (left).
Above, a worker at Cubist’s Lexington facility. Regulators have accepted for review Cubist’s drug for treatment of infections such as methicillin-resistant Staphylococcus aureus (left).Credit: John Guillemin/Bloomberg News/File 2011

This is a summary. To read the whole story subscribe to BostonGlobe.com

In its escalating battle against “superbugs” that resist today’s antibiotics, Cubist Pharmaceuticals Inc. is looking to 2014 as a pivotal year.

US regulators last month accepted for priority review Cubist’s drug application for tedizoid phosphate, an antibiotic for hard-to-treat infections, such as methicillin-resistant Staphylococcus aureus, or MRSA.

Food and Drug Administration officials are set to rule in June on that drug.

Cubist last fall reported positive late-stage clinical trial results for ceftolozane/tazobactam, an antibiotic that targets a potentially large market in urinary tract and intra-abdominal infections. It is preparing to file applications for that experimental treatment in the first half of 2014 in the United States and in the second half in the European Union.

Full story for BostonGlobe.com subscribers.

Get the full story with unlimited access to BostonGlobe.com.

Just 99 cents for four weeks.

Share